Cardiovascular disease

Heart
#Asklepios BioPharmaceutical #Cardiovascular disease #Gene therapy #Heart failure #Phase II trial

One-time gene therapy for heart failure moves to Phase II trial

Gene therapy company Asklepios BioPharmaceutical (AskBio, a subsidiary of Bayer) has announced plans to initiate a Phase II trial of gene therapy AB-1002 for the treatment of congestive heart failure (CHF). GenePHIT (Gene PHosphatase Inhibition Therapy) will evaluate the safety and efficacy of a single intracoronary… Read More

#News

Human heart
#Cardiovascular disease #Ethris #Heart attack #Heart failure #Heqet Therapeutics #Partnership #RNA

Partners hope to regenerate heart tissue using ncRNA

Ethris and Heqet Therapeutics have revealed plans to collaborate on RNA-based therapeutics for heart attack and heart failure, using non coding RNAs (ncRNAs) in regenerating heart tissue. Under the terms of the agreement, Heqet Therapeutics will lead the development of the programme, while Ethris will provide… Read More

#Business & Investment #News

Heart monitor
#Asklepios BioPharmaceutical #Cardiovascular disease #Gene therapy #Heart failure #Phase I trial

One-time gene therapy could change treatment of heart failure

Asklepios BioPharmaceutical (AskBio), a gene therapy subsidiary of Bayer, has presented first-in-human data from a Phase I trial investigating AB-1002 (also known as NAN-101) for the treatment of patients with congestive heart failure (CHF). The data were shared at the American Heart Association Scientific Sessions, which… Read More

#Editor's Choice #News

Cardiovascular system
#Cardiovascular disease #Diabetes #Novo Nordisk #Obesity #Phase III trial

Semaglutide reduces major cardiovascular events by 20%

Semaglutide 2.4mg (Wegovy), a drug approved for weight loss, can reduce the risk of major adverse cardiovascular events (MACE) by 20%, according to new data released by Novo Nordisk. SELECT is a Phase III cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4mg in adults… Read More

#News #Trending News

Gene therapy
#Cardiovascular disease #Gene editing #Genetics / genomics #In vivo #Verve Therapeutics

Single-course in vivo base editing therapy proven to lower cholesterol

A Phase Ib trial has shown low-density lipoprotein cholesterol (LDL-C) reductions up to 55% and blood PCSK9 protein reductions up to 84% after a single infusion of Verve Therapeutics’ Verve-101. The trial participants have heterozygous familial hypercholesterolemia (HeFH), a life-threatening inherited disease characterised by lifelong elevations… Read More

#News #Trending News

Examining a sample under the microscope
#Antibody Fragments #Cardiovascular disease #Nanobodies #Thrombosis #University of Birmingham

Novel nanobody technology boosts thrombosis research

Researchers from the Institute of Cardiovascular Sciences at the University of Birmingham, UK, have produced the first binding molecules (ligands) of defined composition to make platelets clump together in a predictable way. The research team, led by Professor Steve Watson and Dr Eleyna Martin, developed antibody… Read More

#News

Human heart model
#Adverse event #Cardiovascular disease #Drug safety #Drug screening #iPSC #Organ-on-a-chip

Miniature human heart has potential to reshape drug testing

A tiny human heart model could potentially transform cardiovascular research and enable animal-free drug testing. A team of researchers, led by the Hebrew University of Jerusalem (HU), has developed a self-paced, multi-chambered human heart model, approximately half the size of a rice grain. “Integrating… Read More

#Editor's Choice #News

Heart monitor
#AAV #Cardiovascular disease #Collaboration #Evox Therapeutics #Gene therapy #Icahn School of Medicine

Research partners advance AAV gene therapy for heart disease

Evox Therapeutics has agreed a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY, US. The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving… Read More

#News

Heart attack patient with doctor
#ARMGO Pharma #Cardiovascular disease #Heart disease #Phase II trial #Rare disease

Trials of new drug for rare genetic heart disease enter Phase II

ARMGO Pharma has enrolled the first patient in a Phase II proof-of-concept clinical trial using its Rycal ARM210 (also known as S48168), for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT). The trial, performed at the Amsterdam University Medical Center (Amsterdam UMC), Netherlands and the Mayo… Read More

#News

Patient using blood pressure monitor
#Alnylam Pharmaceuticals #blood #Cardiovascular disease #Hypertension #Phase I trial #RNA

Positive Phase I results for RNAi therapeutic in hypertension

Alnylam Pharmaceuticals has revealed results from its Phase I study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension. The results are published in the New England Journal of Medicine (NEJM). The key data showed that… Read More

#News

Kidneys
#AstraZeneca #Cardiovascular disease #Chronic kidney disease (CKD) #Heart failure #Real world data

RWE shows risk of cutting RAASi medication in cardiorenal patients

A real-world evidence (RWE) study has shown the negative consequences of reducing or discontinuing renin-angiotensin-aldosterone system inhibitor (RAASi) medication in patients experiencing hyperkalaemia (HK). One analysis from AstraZeneca’s ZORA study showed that discontinuation of RAASi treatment following a HK episode in cardiorenal patients with chronic kidney… Read More

#News

Cardiovascular system
#Cardiovascular disease #Heart disease #HIV #National Institutes of Health (NIH) #Statins

Daily statin reduces the risk of cardiovascular disease in HIV

A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin medication was found to reduce the increased risk of cardiovascular disease among people living with HIV. This was the first large-scale clinical study to test a primary cardiovascular prevention strategy in… Read More

#Editor's Choice #News

Congestive heart failure
#Cardiovascular disease #FDA #Heart failure #Phase I trial #Sequana Medical #United States

FDA reviews IND for congestive heart failure treatment

Sequana Medical has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for its second-generation DSR product (DSR 2.0) for the treatment of congestive heart failure. Fluid accumulation in heart failure patients is caused by the retention of too much… Read More

#News #Regulatory

Heart monitor
#Cardiovascular disease #CNS #Heart failure #Sleep apnoea #University of Auckland #University of São Paulo

Novel drug shows promise for heart failure and sleep apnoea

A novel drug is showing promise for alleviating heart failure, a common condition associated with sleep apnoea and a reduced lifespan. The drug, known as AF-130, was tested by scientists at University of Auckland, New Zealand and the University of São Paulo, Brazil. They found it… Read More

#News

Atrial fibrillation
#Acesion Pharma #Cardiovascular disease #Clinical trial #Drug discovery #Phase II trial

Success for first new approach to atrial fibrillation for 20 years

The primary endpoint has been achieved in a Phase II trial of AP30663, a first-in-class SK ion channel inhibitor for conversion of atrial fibrillation (AF) to normal sinus rhythm. Acesion Pharma enrolled 63 patients with a current episode of AF in the trial and tested two… Read More

#News

Kim and Bethan Nanion
#ApconiX #Cardiovascular disease #Drug discovery #Podcast #Screening

Podcast: The benefits of early ion channel screening

The latest sponsored DDW Sitting Down With podcast is now available. It features Dr Michael Morton, Director and Co-founder, ApconiX, and Dr Kimberly Rockley of ApconiX, who discuss the benefits of early ion channel screening. The podcast covers the hERG ion channel and its importance in cardiac safety screening… Read More

#News